肺炎后的心血管并发症：聚焦肺炎球菌和心力衰竭。
Cardiovascular complications following pneumonia: focus on pneumococcus and heart failure.
机构信息
Faculty of Health and Medical Sciences, Medical School, The University of Western Australia, Perth.
Department of Advanced Clinical and Translational Cardiovascular Imaging, Harry Perkins Institute of Medical Research, Murdoch.
出版信息
Curr Opin Cardiol. 2019 Mar;34(2):233-239. doi: 10.1097/HCO.0000000000000604.
PURPOSE OF REVIEW
Pneumonia, an inflammatory disease, is the single largest infectious cause of death. Pneumonia has recently been established as an important contributing factor to major adverse cardiovascular events including heart failure. Developing an intermechanistic understanding of pneumonia and cardiovascular disease is crucial for successful future drug therapy and reducing healthcare expenditure.
RECENT FINDINGS
Up to 30% of patients admitted with pneumonia develop cardiovascular complications such as heart failure within 10 years of hospital discharge. Recent mechanistic studies have identified inflammation, pneumolysin, platelet activation, and thrombus formation at the center of cardiovascular disease progression.
SUMMARY
In this review, we will detail current knowledge of the mechanistic interaction between pneumonia and development of cardiovascular disease as well as discuss the current and potential drug therapy targets.
目的综述
肺炎是一种炎症性疾病，是导致死亡的最大单一感染原因。最近的研究表明，肺炎是心力衰竭等主要不良心血管事件的重要致病因素之一。因此，深入了解肺炎和心血管疾病的发病机制对于未来成功的药物治疗和降低医疗支出至关重要。
最近的发现
多达 30%的肺炎住院患者在出院后 10 年内会出现心力衰竭等心血管并发症。最近的机制研究表明，炎症、肺炎球菌溶血素、血小板激活和血栓形成是心血管疾病进展的核心。
总结
在这篇综述中，我们将详细介绍肺炎与心血管疾病发展之间的机制相互作用的现有知识，并讨论当前和潜在的药物治疗靶点。
Zotero 插件